GlassScriptPhysician profile
Scott R Cooper
NPI 1235175530
$3,308.13
in general payments reported to CMS, 2019-2025
34 companies · $363 in 2025
The $363 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $107 · 2021: $197 · 2022: $386 · 2023: $968 · 2024: $828 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $713.29 | 2020-2024 | Senza |
| Medtronic, INC. | $306.98 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Abbott Laboratories | $281.65 | 2019-2025 | Eterna, Ionicrf |
| Relievant Medsystems, INC. | $210.23 | 2022-2023 | Intracept |
| Abbvie INC. | $198.88 | 2022-2025 | Botox |
| Spr Therapeutics, INC | $178.80 | 2023-2024 | Sprint Pns System |
| Vertos Medical, INC. | $163.07 | 2023-2024 | Mild Device Kit |
| Boston Scientific Corporation | $158.06 | 2024-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Painteq LLC | $152.47 | 2022-2024 | Painteq |
| Curonix LLC | $124.79 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Fidia Pharma USA INC. | $93.90 | 2019-2020 | |
| Saluda Medical Americas, INC. | $88.14 | 2025 | Evoke |
| Allergan, INC. | $86.42 | 2019-2020 | |
| Radius Health, INC. | $69.43 | 2019 | |
| Assertio Therapeutics, INC. | $53.34 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $49.13 | 2024-2025 | Vyepti |
| Medtronic USA, INC. | $40.99 | 2019 | |
| Merz Pharmaceuticals, LLC | $38.12 | 2025 | Xeomin |
| Pfizer INC. | $32.04 | 2019 | |
| Azurity Pharmaceuticals, INC. | $29.72 | 2025 | Horizant |
| Amgen INC. | $29.03 | 2019 | |
| Averitas Pharma INC. | $24.45 | 2023 | Qutenza |
| Nalu Medical, INC. | $23.82 | 2024 | Nalu Neurostimulation System |
| Vertex Pharmaceuticals Incorporated | $17.59 | 2025 | |
| Spinal Simplicity, LLC | $17.30 | 2025 | Ha Minuteman G3-R |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.37 | 2019 | |
| Depuy Synthes Sales INC. | $15.79 | 2024 | Monovisc, Orthovisc |
| Daiichi Sankyo INC. | $15.26 | 2019 | |
| Biodelivery Sciences International, INC. | $15.18 | 2019 | |
| Collegium Pharmaceutical, INC. | $13.78 | 2019 | |
| Tersera Therapeutics LLC | $13.31 | 2019 | |
| Avanos Medical | $12.50 | 2022 | |
| Sentynl Therapeutics, INC. | $12.25 | 2019 | |
| Scilex Pharmaceuticals INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.